SilybinCAS: 22888-70-6
MF: C25H22O10
MW: 482.44
A major active constituent of silymarin which inhibits mitogen-activated protein kinase (MAPK).

Silybin (CAS 22888-70-6)

Silybin | CAS 22888-70-6 is rated 5.0 out of 5 by 1.
  • y_2020, m_1, d_16, h_20
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.4
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_202812, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 130ms
  • REVIEWS, PRODUCT
5
1
4
0
3
0
2
0
1
0
Synonym: Silibinin; 2,3-Dihydro-3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-6-(3,5,7-trihydroxy-4-oxobenzopyran-2-yl)benzodioxin; Silymarin
Application: A major active constituent of silymarin which inhibits mitogen-activated protein kinase (MAPK)
CAS Number: 22888-70-6
Purity: >98%
Molecular Weight: 482.44
Molecular Formula: C25H22O10
* Refer to Certificate of Analysis for lot specific data (including water content).
Submit a review for this product and receive 15 CruzCredits

Silybin is an inhibitor of a wide variety of proteins, many of which are heavily involved in xenobiotic efflux and metabolism. Silybin is an inhibitor of P-glycoprotein-mediated cellular efflux and also inhibits xenobiotic oxidation by the CYP (cytochrome P450) superfamily of enzymes. This helps to contribute the apoptotic activity of this compound, which has been shown to be effective against a wide variety of cancer cell lines. Silybin is an inhibitor of 5-LO.


References

1. Wagner, H., et al. 1968. Arzneimittelforschung. 18: 688-696. PMID: 5755805
2. Dehmlow, C., et al. 1996. Hepatology. 23: 749-754. PMID: 8666328
3. Zi X., et al. 1999. Proc Natl Acad Sci U.S.A. 96: 7490-7495. PMID: 10377442
4. Maitrejean, M., et al. 2000. Bioorg. Med. Chem. Lett. 10: 157-160. PMID: 10673101
5. Dhanalakshmi, S., et al. 2002. Oncogene 21: 1759-1767. PMID: 11896607
6. Agarwal, C., et al. 2003. Oncogene 22: 8271-8282. PMID: 14614451
7. Qi, L., et al. 2003. Cancer Biol. Ther. 2: 526-531. PMID: 14614320
8. Tyagi, A.K., et al. 2003. Biochem Biophys Res.Commun. 312: 1178-1184.
9. Mallikarjuna, G., et al. 2004. Cancer Res. 64: 6349-6356. PMID: 15342425
10. Dhanalakshmi, S., et al. 2005. J. Biol. Chem. 280: 20375-20383. PMID: 15792956
11. Chen, P.N., et al. 2006. J. Dent. Res. 85: 220-225. PMID: 1649806
12. Hoh, C., et al. 2006. Clin. Cancer Res. 12: 2944-2950. PMID: 16675592
13. Li, L.H., et al. 2006. Biol. Pharm. Bull. 29: 1096-1101. PMID: 16755000
14. Singh, R.P., et al. 2006. Mol. Cancer Ther. 5: 1145-1153. PMID: 16731746
15. Tyagi, A., et al. 2006. Carcinogenesis. 27: 2269-2280. PMID: 16777994
16. Agarwal, C., et al. 2007. Carcinogenesis. 28: 1463-1470. PMID: 17341659
17. Lah, J.J., et al. 2007. World J. Gastroenterol. 13: 5299-5305. PMID: 17879397
18. Lee, S.O., et al. 2007. Biochem Biophys Res. Commun. 354: 165-171. PMID: 17214970
19. Min, K., et al. 2007. Arch. Pharm. Res. 30: 1265-1271. PMID: 18038905
20. Son, Y.G., et al. 2007. Cancer Res. 67: 8274-8284. PMID: 17804742
21. Tyagi, A., et al. 2008. Pharm. Res. 25: 2143-2150. PMID: 18253818

Physical State :
Solid
Derived From :
Silybum marianum.
Solubility :
Soluble in 100% ethanol (0.1mg/ml), DMSO (10mg/ml), dimethyl formamide (20mg/ml), acetone or methanol; 0.5mg/ml soluble in a 1:9 solution of dimethyl formamide:PBS (pH 7.2) (dilute the dimethyl formamide solution with PBS).
Storage :
Store at -20° C
Melting Point :
167° C
Refractive Index :
n20D 1.68 (Predicted)
pK Values :
pKa: 7.39 (Predicted)
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
PubChem CID :
31553
MDL Number :
MFCD00872186
EC Number :
245-302-5
SMILES :
COC1=C(C=CC(=C1)[[email protected]@H]2[[email protected]](OC3=C(O2)C=C(C=C3)[[email protected]@H]4[[email protected]](C(=O)C5=C(C=C(C=C5O4)O)O)O)CO)O

Download SDS (MSDS)

Certificate of Analysis

Adobe Acrobat Reader is required to reliably view,
print and comment on PDF documents

Silybin  Product Citations

See how others have used Silybin. Click on the entry to view the PubMed entry .

Citations 1 to 3 of 3 total

PMID: # 24798868  Liang, Z. et al. 2014. Mol. Cancer Ther. 13: 1860-72.

PMID: # 17916909  Singh, RP. et al. 2007. Carcinogenesis. 28: 2567-2574.

PMID: # 14504208  Singh, RP. et al. 2003. Cancer Epidemiol. Biomarkers Prev. 12: 933-939.

Citations 1 to 3 of 3 total
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 116ms
  • QUESTIONS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of 5 by from Singh Singh, et. al. (PubMed ID 17916909) found that treating nude mice before and/or after of human prostate carcinoma PC-3 tumor xenograft implantation inhibited the tumor growth rate; showing a decrease in tumor volume and tumor weight (per mouse). -SCBT Publication Review
Date published: 2015-03-01
  • y_2020, m_1, d_16, h_20
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.4
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_202812, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 13ms
  • REVIEWS, PRODUCT

Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.